Rui Liu1, David M Umbach2, Alexander I Tröster3, Xuemei Huang4, Honglei Chen5. 1. Southern Connecticut State University, New Haven, CT, USA. Electronic address: liur1@southernct.edu. 2. Biostatistics Branch of the National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA. 3. Department of Clinical Neuropsychology, Barrow Neurological Institute, Phoenix, AZ, USA. 4. Department of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA. 5. Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, USA.
Abstract
BACKGROUND: Non-motor symptoms (NMS) are common in Parkinson's disease (PD), but their relationships to nigrostriatal degeneration remain largely unexplored. METHODS: We evaluated 18 NMS scores covering 5 major domains in relation to concurrent and future dopamine transporter (DAT) imaging in 344 PD patients from the Parkinson's Progression and Markers Initiative (PPMI). We standardized NMS assessments into z-scores for side-by-side comparisons. Patients underwent sequential DaTSCAN imaging at enrollment and at months 12, 24, and 48. Specific binding ratios (SBR) were calculated using the occipital lobe reference region. We evaluated the association of striatal DAT binding at the four time points with each baseline NMS using mixed-effects regression models. RESULTS: Multiple baseline NMS were significantly associated with DAT binding at baseline and at follow-up scans. REM sleep behavior disorder (RBD) symptoms showed the strongest association - mean striatal SBR declined with increasing RBD symptom z-score (average of time-point-specific slopes per unit change in z-score: βAVG = -0.083, SE = 0.017; p < 0.0001). In addition, striatal DAT binding was linearly associated with increasing baseline z-scores: positively for the memory (βAVG=0.055, SE = 0.022; p = 0.01) and visuospatial (βAVG=0.044, SE = 0.020; p = 0.03) cognitive domains, and negatively for total anxiety (βAVG= -0.059, SE = 0.018; p = 0.001). Striatal DAT binding showed curvilinear associations with odor identification, verbal discrimination recognition, and autonomic dysfunction z-scores (p = 0.001, p = 0.0009, and p = 0.0002, respectively). Other NMS were not associated with DAT binding. CONCLUSIONS: Multiple NMS, RBD symptoms in particular, are associated with nigrostriatal dopaminergic changes in early PD.
BACKGROUND: Non-motor symptoms (NMS) are common in Parkinson's disease (PD), but their relationships to nigrostriatal degeneration remain largely unexplored. METHODS: We evaluated 18 NMS scores covering 5 major domains in relation to concurrent and future dopamine transporter (DAT) imaging in 344 PDpatients from the Parkinson's Progression and Markers Initiative (PPMI). We standardized NMS assessments into z-scores for side-by-side comparisons. Patients underwent sequential DaTSCAN imaging at enrollment and at months 12, 24, and 48. Specific binding ratios (SBR) were calculated using the occipital lobe reference region. We evaluated the association of striatal DAT binding at the four time points with each baseline NMS using mixed-effects regression models. RESULTS: Multiple baseline NMS were significantly associated with DAT binding at baseline and at follow-up scans. REM sleep behavior disorder (RBD) symptoms showed the strongest association - mean striatal SBR declined with increasing RBD symptom z-score (average of time-point-specific slopes per unit change in z-score: βAVG = -0.083, SE = 0.017; p < 0.0001). In addition, striatal DAT binding was linearly associated with increasing baseline z-scores: positively for the memory (βAVG=0.055, SE = 0.022; p = 0.01) and visuospatial (βAVG=0.044, SE = 0.020; p = 0.03) cognitive domains, and negatively for total anxiety (βAVG= -0.059, SE = 0.018; p = 0.001). Striatal DAT binding showed curvilinear associations with odor identification, verbal discrimination recognition, and autonomic dysfunction z-scores (p = 0.001, p = 0.0009, and p = 0.0002, respectively). Other NMS were not associated with DAT binding. CONCLUSIONS: Multiple NMS, RBD symptoms in particular, are associated with nigrostriatal dopaminergic changes in early PD.
Authors: Ronald B Postuma; Dag Aarsland; Paolo Barone; David J Burn; Christopher H Hawkes; Wolfgang Oertel; Tjalf Ziemssen Journal: Mov Disord Date: 2012-04-15 Impact factor: 10.338
Authors: Lama M Chahine; Daniel Weintraub; Keith A Hawkins; Andrew Siderowf; Shirley Eberly; David Oakes; John Seibyl; Matthew B Stern; Kenneth Marek; Danna Jennings Journal: Mov Disord Date: 2015-08-21 Impact factor: 10.338
Authors: Danna Jennings; Andrew Siderowf; Matthew Stern; John Seibyl; Shirley Eberly; David Oakes; Kenneth Marek Journal: JAMA Neurol Date: 2017-08-01 Impact factor: 18.302
Authors: Alex Iranzo; Eduard Tolosa; Ellen Gelpi; José Luis Molinuevo; Francesc Valldeoriola; Mónica Serradell; Raquel Sanchez-Valle; Isabel Vilaseca; Francisco Lomeña; Dolores Vilas; Albert Lladó; Carles Gaig; Joan Santamaria Journal: Lancet Neurol Date: 2013-04-03 Impact factor: 44.182
Authors: Mike A Nalls; Cory Y McLean; Jacqueline Rick; Shirley Eberly; Samantha J Hutten; Katrina Gwinn; Margaret Sutherland; Maria Martinez; Peter Heutink; Nigel M Williams; John Hardy; Thomas Gasser; Alexis Brice; T Ryan Price; Aude Nicolas; Margaux F Keller; Cliona Molony; J Raphael Gibbs; Alice Chen-Plotkin; Eunran Suh; Christopher Letson; Massimo S Fiandaca; Mark Mapstone; Howard J Federoff; Alastair J Noyce; Huw Morris; Vivianna M Van Deerlin; Daniel Weintraub; Cyrus Zabetian; Dena G Hernandez; Suzanne Lesage; Meghan Mullins; Emily Drabant Conley; Carrie A M Northover; Mark Frasier; Ken Marek; Aaron G Day-Williams; David J Stone; John P A Ioannidis; Andrew B Singleton Journal: Lancet Neurol Date: 2015-08-10 Impact factor: 44.182
Authors: Charity G Patterson; Elizabeth Joslin; Alexandra B Gil; Wendy Spigle; Todd Nemet; Lana Chahine; Cory L Christiansen; Ed Melanson; Wendy M Kohrt; Martina Mancini; Deborah Josbeno; Katherine Balfany; Garett Griffith; Mac Kenzie Dunlap; Guillaume Lamotte; Erin Suttman; Danielle Larson; Chantale Branson; Kathleen E McKee; Li Goelz; Cynthia Poon; Barbara Tilley; Un Jung Kang; Malú Gámez Tansey; Nijee Luthra; Caroline M Tanner; Jacob M Haus; Giamila Fantuzzi; Nikolaus R McFarland; Paulina Gonzalez-Latapi; Tatiana Foroud; Robert Motl; Michael A Schwarzschild; Tanya Simuni; Kenneth Marek; Anna Naito; Codrin Lungu; Daniel M Corcos Journal: Trials Date: 2022-10-06 Impact factor: 2.728